77 related articles for article (PubMed ID: 38687369)
1. Immune cell infiltration and prognostic index in cervical cancer: insights from metabolism-related differential genes.
Ma B; Ren C; Yin Y; Zhao S; Li J; Yang H
Front Immunol; 2024; 15():1411132. PubMed ID: 38840928
[TBL] [Abstract][Full Text] [Related]
2. A novel signature incorporating genes related to lipid metabolism and immune for prognostic and functional prediction of breast cancer.
Zhao X; Yan L; Yang Z; Zhang H; Kong L; Zhang N; He Y
Aging (Albany NY); 2024 May; 16(10):8611-8629. PubMed ID: 38771140
[TBL] [Abstract][Full Text] [Related]
3. Profiling of Tumor-Infiltrating Immune Cells and Their Impact on Survival in Glioblastoma Patients Undergoing Immunotherapy with Dendritic Cells.
Peres N; Lepski GA; Fogolin CS; Evangelista GCM; Flatow EA; de Oliveira JV; Pinho MP; Bergami-Santos PC; Barbuto JAM
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791312
[TBL] [Abstract][Full Text] [Related]
4. Glioblastoma-Infiltrating CD8+ T Cells Are Predominantly a Clonally Expanded GZMK+ Effector Population.
Wang AZ; Mashimo BL; Schaettler MO; Sherpa ND; Leavitt LA; Livingstone AJ; Khan SM; Li M; Anzaldua-Campos MI; Bradley JD; Leuthardt EC; Kim AH; Dowling JL; Chicoine MR; Jones PS; Choi BD; Cahill DP; Carter BS; Petti AA; Johanns TM; Dunn GP
Cancer Discov; 2024 Jun; 14(6):1106-1131. PubMed ID: 38416133
[TBL] [Abstract][Full Text] [Related]
5. T cell-mediated tumor killing based signature to predict the prognosis and immunotherapy for glioblastoma.
Liu H; Shi K; Wei Z; Zhang Y; Li J
Heliyon; 2024 May; 10(10):e31207. PubMed ID: 38813229
[TBL] [Abstract][Full Text] [Related]
6. Identification of the CD8+ T-cell Related Signature for Predicting the Prognosis of Gastric Cancer Based on Integrated Analysis of Bulk and Single-cell RNA Sequencing Data.
Zhu ZG; Wang Z; Wu Q; Miao DL; Jin YQ; Chen L
J Immunother; 2024 May; ():. PubMed ID: 38809517
[TBL] [Abstract][Full Text] [Related]
7. Identification of transcriptomic signatures associated with glioblastoma recurrence.
Lawler SE
Neuro Oncol; 2024 Jun; 26(6):989-990. PubMed ID: 38470202
[No Abstract] [Full Text] [Related]
8. Deciphering glycosylation-driven prognostic insights and therapeutic prospects in glioblastoma through a comprehensive regulatory model.
Jin X; Chen Z; Zhao H
Front Oncol; 2024; 14():1288820. PubMed ID: 38841168
[TBL] [Abstract][Full Text] [Related]
9. Understanding glioblastoma at the single-cell level: Recent advances and future challenges.
Yabo YA; Heiland DH
PLoS Biol; 2024 May; 22(5):e3002640. PubMed ID: 38814900
[TBL] [Abstract][Full Text] [Related]
10. Drivers of heterogeneity in the glioblastoma immune microenvironment.
Brosque A; Friedmann-Morvinski D
Curr Opin Cell Biol; 2023 Dec; 85():102279. PubMed ID: 37984008
[TBL] [Abstract][Full Text] [Related]
11. TREM2 function in glioblastoma immune microenvironment: Can we distinguish reality from illusion?
Ghosh S; Rothlin CV
Neuro Oncol; 2024 May; 26(5):840-842. PubMed ID: 38290471
[No Abstract] [Full Text] [Related]
12. Prognosis and immunotherapy in melanoma based on selenoprotein k-related signature.
Liu Y; Xia H; Wang Y; Han S; Liu Y; Zhu S; Wu Y; Luo J; Dai J; Jia Y
Int Immunopharmacol; 2024 Jun; 137():112436. PubMed ID: 38857552
[TBL] [Abstract][Full Text] [Related]
13. Characterizing cell subsets using marker enrichment modeling.
Diggins KE; Greenplate AR; Leelatian N; Wogsland CE; Irish JM
Nat Methods; 2017 Mar; 14(3):275-278. PubMed ID: 28135256
[TBL] [Abstract][Full Text] [Related]
14. A novel immune cell signature for predicting glioblastoma after radiotherapy prognosis and guiding therapy.
Huang R; Lu X; Sun X; Wu H
Int J Immunopathol Pharmacol; 2024; 38():3946320241249395. PubMed ID: 38687369
[No Abstract] [Full Text] [Related]
15. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
16. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.
Jeanmougin M; Håvik AB; Cekaite L; Brandal P; Sveen A; Meling TR; Ågesen TH; Scheie D; Heim S; Lothe RA; Lind GE
Mol Oncol; 2020 May; 14(5):1016-1027. PubMed ID: 32171051
[TBL] [Abstract][Full Text] [Related]
17. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
Front Immunol; 2021; 12():557994. PubMed ID: 34220791
[TBL] [Abstract][Full Text] [Related]
18. Construction of Interferon-Gamma-Related Gene Signature to Characterize the Immune-Inflamed Phenotype of Glioblastoma and Predict Prognosis, Efficacy of Immunotherapy and Radiotherapy.
Ji H; Ba Y; Ma S; Hou K; Mi S; Gao X; Jin J; Gong Q; Liu T; Wang F; Liu Z; Li S; Du J; Hu S
Front Immunol; 2021; 12():729359. PubMed ID: 34566988
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk Between Tumor-Associated Microglia/Macrophages and CD8-Positive T Cells Plays a Key Role in Glioblastoma.
Tu S; Lin X; Qiu J; Zhou J; Wang H; Hu S; Yao Y; Wang Y; Deng Y; Zhou Y; Shao A
Front Immunol; 2021; 12():650105. PubMed ID: 34394072
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
